144 related articles for article (PubMed ID: 38113467)
1. A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study.
Enshaei A; Joy M; Butler E; Kirkwood AA; Messina M; Pavoni C; Morgades M; Harrison CJ; Foà R; Ribera JM; Chiaretti S; Bassan R; Fielding AK; Moorman AV
Blood Adv; 2024 Mar; 8(5):1155-1166. PubMed ID: 38113467
[TBL] [Abstract][Full Text] [Related]
2. A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia.
Enshaei A; O'Connor D; Bartram J; Hancock J; Harrison CJ; Hough R; Samarasinghe S; den Boer ML; Boer JM; de Groot-Kruseman HA; Marquart HV; Noren-Nystrom U; Schmiegelow K; Schwab C; Horstmann MA; Escherich G; Heyman M; Pieters R; Vora A; Moppett J; Moorman AV
Blood; 2020 Apr; 135(17):1438-1446. PubMed ID: 32315382
[TBL] [Abstract][Full Text] [Related]
3. Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials.
Enshaei A; Vora A; Harrison CJ; Moppett J; Moorman AV
Lancet Haematol; 2021 Nov; 8(11):e828-e839. PubMed ID: 34715050
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Giebel S; Marks DI; Boissel N; Baron F; Chiaretti S; Ciceri F; Cornelissen JJ; Doubek M; Esteve J; Fielding A; Foa R; Gorin NC; Gökbuget N; Hallböök H; Hoelzer D; Paravichnikova E; Ribera JM; Savani B; Rijneveld AW; Schmid C; Wartiovaara-Kautto U; Mohty M; Nagler A; Dombret H
Bone Marrow Transplant; 2019 Jun; 54(6):798-809. PubMed ID: 30385870
[TBL] [Abstract][Full Text] [Related]
5. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
6. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia.
Rabin KR; Gramatges MM; Borowitz MJ; Palla SL; Shi X; Margolin JF; Zweidler-McKay PA
Pediatr Blood Cancer; 2012 Sep; 59(3):468-74. PubMed ID: 22102553
[TBL] [Abstract][Full Text] [Related]
7. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913.
Chiaretti S; Messina M; Della Starza I; Piciocchi A; Cafforio L; Cavalli M; Taherinasab A; Ansuinelli M; Elia L; Albertini Petroni G; La Starza R; Canichella M; Lauretti A; Puzzolo MC; Pierini V; Santoro A; Spinelli O; Apicella V; Capria S; Di Raimondo F; De Fabritiis P; Papayannidis C; Candoni A; Cairoli R; Cerrano M; Fracchiolla N; Mattei D; Cattaneo C; Vitale A; Crea E; Fazi P; Mecucci C; Rambaldi A; Guarini A; Bassan R; Foà R
Haematologica; 2021 Jun; 106(6):1559-1568. PubMed ID: 32467145
[TBL] [Abstract][Full Text] [Related]
8. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors for Relapse of Childhood B Cell Acute Lymphoblastic Leukemia.
Zhang R; Zhu H; Yuan Y; Zhao J; Yang X; Tian Z
Med Sci Monit; 2020 Jul; 26():e923271. PubMed ID: 32619211
[TBL] [Abstract][Full Text] [Related]
10. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
[TBL] [Abstract][Full Text] [Related]
11. The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols.
Ampatzidou M; Papadhimitriou SI; Paisiou A; Paterakis G; Tzanoudaki M; Papadakis V; Florentin L; Polychronopoulou S
Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174980
[TBL] [Abstract][Full Text] [Related]
12. Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL.
Giebel S; Stella-Holowiecka B; Krawczyk-Kulis M; Gökbuget N; Hoelzer D; Doubek M; Mayer J; Piatkowska-Jakubas B; Skotnicki AB; Dombret H; Ribera JM; Piccaluga PP; Czerw T; Kyrcz-Krzemien S; Holowiecki J;
Bone Marrow Transplant; 2010 Jun; 45(6):1095-101. PubMed ID: 19855438
[TBL] [Abstract][Full Text] [Related]
13. Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia.
O'Connor D; Enshaei A; Bartram J; Hancock J; Harrison CJ; Hough R; Samarasinghe S; Schwab C; Vora A; Wade R; Moppett J; Moorman AV; Goulden N
J Clin Oncol; 2018 Jan; 36(1):34-43. PubMed ID: 29131699
[TBL] [Abstract][Full Text] [Related]
14. Newly proposed threshold and validation of white blood cell count at diagnosis for Philadelphia chromosome-positive acute lymphoblastic leukemia: risk assessment of relapse in patients with negative minimal residual disease at transplantation-a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSTCT.
Akahoshi Y; Arai Y; Nishiwaki S; Tachibana T; Shinohara A; Doki N; Uchida N; Tanaka M; Kanda Y; Shiratori S; Ozawa Y; Shono K; Katayama Y; Tanaka J; Fukuda T; Atsuta Y; Kako S
Bone Marrow Transplant; 2021 Nov; 56(11):2842-2848. PubMed ID: 34331021
[TBL] [Abstract][Full Text] [Related]
15. Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A; Hatta Y; Imai C; Oshima K; Okamoto Y; Deguchi T; Hashii Y; Fukushima T; Hori T; Kiyokawa N; Kato M; Saito S; Anami K; Sakamoto T; Kosaka Y; Suenobu S; Imamura T; Kada A; Saito AM; Manabe A; Kiyoi H; Matsumura I; Koh K; Watanabe A; Miyazaki Y; Horibe K
Lancet Haematol; 2023 Jun; 10(6):e419-e432. PubMed ID: 37167992
[TBL] [Abstract][Full Text] [Related]
16. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
17. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
Locatelli F; Eckert C; Hrusak O; Buldini B; Sartor M; Zugmaier G; Zeng Y; Pilankar D; Morris J; von Stackelberg A
Pediatr Blood Cancer; 2022 Aug; 69(8):e29715. PubMed ID: 35482538
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.
Pui CH; Pei D; Raimondi SC; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Gruber TA; Leung WH; Yang JJ; Downing JR; Evans WE; Relling MV; Campana D
Leukemia; 2017 Feb; 31(2):333-339. PubMed ID: 27560110
[TBL] [Abstract][Full Text] [Related]
19. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia.
Steenbergen EJ; Verhagen OJ; van Leeuwen EF; van den Berg H; Behrendt H; Slater RM; von dem Borne AE; van der Schoot CE
Leukemia; 1995 Oct; 9(10):1726-34. PubMed ID: 7564517
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
